Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | ($32.7M) | ($42.9M) | ($34.6M) | ($85.5M) | ($26.2M) | ($47.6M) | ($43.5M) | ($57.6M) | ($106.0M) | ($89.2M) | ($360.4M) | ($290.1M) | ($410.1M) | ($490.9M) | ($761.5M) | ($886.1M) | ($858.3M) | ($852.8M) | ($1,131.2M) | ($440.2M) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Alnylam Pharmaceuticals, Inc.'s last 12-month Net Income is ($332.3M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Alnylam Pharmaceuticals, Inc.'s Net Income growth was (34.8%). The average annual Net Income growth rates for Alnylam Pharmaceuticals, Inc. have been (27.6%) over the past three years, (16.6%) over the past five years.
Over the last year, Alnylam Pharmaceuticals, Inc.'s Net Income growth was (34.8%), which is lower than industry growth of (0.1%). It indicates that Alnylam Pharmaceuticals, Inc.'s Net Income growth is Bad.